
Last week’s announcement from Danish Leo Pharma about a drastic change in business strategies, is an attempt to reach out to patients, create a greater level of satisfaction and ultimately secure more clients for the company’s products, says head of sales and marketing, Lars Olsen, in an interview with Medwatch.
The resignation of 300 positions within the company across Europe is a part of that change, explains the executive. Those resignations are not to be seen as cutbacks, however, but rather as an adaptation to strategies and business models used by the company.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app